Abstracts tagged "ACPA and rheumatoid arthritis (RA)"

Abstract Number: 2108 • 2019 ACR/ARP Annual Meeting
Risk Factors for Pulmonary Nontuberculous Mycobacterial Disease in Rheumatoid Arthritis Patients
Yoichi Nakayama¹, Eisaku Tanaka ², Masakuni Ueyama ³, Satoru Terada ², Takashi Inao ², Yusuke Kaji ², Takehiro Yasuda ², Seishu Hashimoto ², Takashi Hajiro ² and Yoshio Taguchi ², ¹Tenri Hospital, Department of General Internal Medicine, Tenri, Nara, Japan, ²Tenri Hospital, Department of Respiratory Medicine, Tenri, Nara, Japan, ³Tenri Hospital, Department of Respiratory Medicine, Tenri, Japan
Background/Purpose: Rheumatoid arthritis (RA) patients have increased susceptibility to infection by pulmonary nontuberculous mycobacterial disease (pNTM) compared with the healthy population. The reason for this…
Abstract Number: 1341 • 2017 ACR/ARHP Annual Meeting
The Impact of Anti-Cyclic Citrullinated Peptide Seropositivity on Erosion Prevalence Among Patients with RA of Varying Disease Duration
Leslie R Harrold¹, K Price², Heather J. Litman³, SE Connolly², E Alemao², Sabrina Rebello⁴, W Hua³ and Joel Kremer⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Bristol-Myers Squibb, Princeton, NJ, ³Corrona, Southborough, MA, ⁴Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Little is known regarding the prevalence of erosive disease in a contemporary cohort of patients with RA and whether erosive disease prevalence differs by…
Abstract Number: 2407 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Elevated Anti-Cyclic Citrullinated Protein Antibody Titers in Patients with Pulmonary Hypertension
Sarah Ifteqar¹, Megan Krause², Paul Schmidt³, Lewis Satterwhite⁴ and Mehrdad Maz⁵, ¹Department of Medicine, Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Department of Medicine, Division of Allergy, Clinical Immunology and Rheumatology, The University of Kansas Medical Center, Kansas City, KS, ³Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS, ⁴Department of Medicine, Division of Pulmonary and Critical Care, The University of Kansas Medical Center, Kansas City, KS, ⁵Allergy, Clinical Immunology, and Rheumatology, Division of Allergy, Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Pulmonary hypertension (PH) is a disease entity characterized by elevated pulmonary artery pressure, which often results in right ventricular failure. As part of PH…
Abstract Number: 2229 • 2016 ACR/ARHP Annual Meeting
Economic Burden of Rheumatoid Arthritis Is Higher for ACPA-Positive Patients
J Shafrin¹, N Hou¹, MG Tebeka¹, L Rosenblatt², K Price², C Patel³ and K Michaud⁴, ¹Precision Health Economics, Los Angeles, CA, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Princeton, NY, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) have emerged as promising serological biomarkers of rapidly progressing RA and are associated with more severe disease and joint damage.…
Abstract Number: 443 • 2014 ACR/ARHP Annual Meeting
Sputum Anti-Citrullinated Protein Antibodies in Patients with Long Standing Rheumatoid Arthritis
Ari Polachek¹, Wilma Vree Egberts², Elizabeth Fireman³, Daphna Paran⁴, Ido Drokman⁵, Ilana Kaufman⁶, Irena Wigler⁷, Dan Caspi⁸, David Levartovsky⁹, Ger JM Pruijn¹⁰ and Ori Elkayam¹¹, ¹Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel, ²Radboud University Medical Centre, Nijmegen, Israel, ³Pulmonary and Allergic diseases, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁵Radiology, Sourasky Medical Center, Tel-Aviv, Israel, ⁶Sourasky Medical Center, Tel-Aviv, Israel, ⁷Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁸Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁹Rheumatology, Tel Aviv Medical Ctr, Tel Aviv, Israel, ¹⁰Department of Biomolecular Chemistry, Radboud University, Nijmegen, Netherlands, ¹¹Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
Background/Purpose: The lung has been implicated in the pathogenesis of rheumatoid arthritis (RA). The aim of this study was to evaluate the presence of autoantibodies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].